← Back to Search

Cell Therapy

Cultured Treg cells for Graft-versus-Host Disease

Phase 1
Waitlist Available
Led By Joseph Pidala, MD, PhD
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial is testing if Tregs can prevent GVHD in HLA identical sibling transplants.

Eligible Conditions
  • Graft-versus-Host Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximally Tolerated dose (MTD)
Secondary outcome measures
Acute GVHD incidence
Non-relapse Mortality
Overall Survival (OS)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cultured Treg cellsExperimental Treatment1 Intervention
Co-culturing of recipient dendritic cells and donor Treg cells given prior to allogeneic stem cell transplant
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cultured Treg cells
2014
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
543 Previous Clinical Trials
135,457 Total Patients Enrolled
Joseph Pidala, MD, PhDPrincipal InvestigatorMoffitt Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
2014. "Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01795573.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top